ADARx Pharmaceuticals to Present at the UBS Global Biopharma Conference
ADARx Pharmaceuticals (ADRX) will participate in a fireside chat at the UBS Global Biopharma Conference on November 16, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ADARx Pharmaceuticals (ADRX) will participate in a fireside chat at the UBS Global Biopharma Conference on November 16, 2026.
President and Chief Executive Officer Zhen Li will speak in London at 2:00 p.m. GMT. A live webcast will be available on the Events page of the company’s investor website, with a replay archived on its website for 90 days.
Details
Market Reaction – ADRX
On Nov 9, the day this news came out, the latest delayed price for ADRX is 2.49% above the previous close. Our momentum scanner has recorded 3 alerts for this stock so far that day. The latest delayed price is $13.56. Relative volume is elevated at 2.5x what this stock usually trades by this time of day.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Terms
sirna medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 09, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, today announced that Zhen Li, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the UBS Global Biopharma Conference in London, UK on Monday, November 16, at 2:00 p.m. GMT.
A live webcast will be available on the Events page of ADARx’s investor website. A replay of the conference webcast will be archived on the company's website for 90 days.
About ADARx Pharmaceuticals
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. We are focused on advancing and expanding our pipeline of highly potent, selective and durable siRNA therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. Our three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and our two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond our named programs, we plan to continue to leverage our proprietary technologies to strategically expand our pipeline of next-generation siRNA therapeutics. Our goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.
Contacts Investors: ir@adarx.com Media: teri@redhousecomms.com